IRVINE, Calif., April 24, 2017 (GLOBE NEWSWIRE) -- Helping clinicians meet treatment needs, Central Admixture Pharmacy Services, Inc. (CAPS®) will introduce Tromethamine at this year’s American Society of ExtraCorporeal Technology conference. Representatives from CAPS will be at booth #1101 at the 55th AmSECT conference, April 29-May 2, at the Hynes Convention Center in Boston.
“Tromethamine 0.3 molar solution is now available from CAPS, where improving patient care and outcomes have been a tradition for more than 25 years,” said Mike Koch, Senior Vice President, CAPS Professional Services. “In keeping with that commitment, we’re supplying this important medication to help clinicians.”
CAPS Tromethamine solution is now available and supplied as a single dose 0.3M 50mL solution in a 60 mL syringe with a tamper-evident syringe cap. The cap easily unlocks, just prior to syringe use, by pulling the clear protective barrier off and removing the red syringe cap.
Like all CAPS sterile compounded drugs, Tromethamine undergoes CAPS’ Test, Hold and Release (THRSM) program which is designed to ensure that every compounded drug batch from its 503B outsourcing facilities meets the new standards for cGMP release testing for sterility, potency, and endotoxin testing prior to release and shipment. CAPS also offers a Certificate of Release for each batch to give customers peace of mind.
CAPS, a B. Braun company, was among the first outsourcing admixture pharmacies in the nation to adopt release testing.
About CAPS®
CAPS is the nation’s largest network of outsourcing admixture pharmacies. A pioneer in the outsourcing of CSPs, CAPS was founded in 1991, and delivers high-quality, same-day, admixture services and solutions to hospitals and outpatient facilities across the nation. CAPS has two 503B outsourcing facilities that are registered with the FDA to provide sterile compounding services. CAPS also has 22 state-licensed 503A regional pharmacies that dispense labeled, patient-specific prescriptions including parenteral nutrition and chemotherapy. To learn more, visit www.capspharmacy.com.
About B. Braun
B. Braun Medical Inc., a leader in infusion therapy and pain management, develops, manufactures, and markets innovative medical products and services to the health care industry. The company is committed to eliminating preventable treatment errors and enhancing patient, clinician and environmental safety. B. Braun Medical is headquartered in Bethlehem, PA, and is part of the B. Braun Group of Companies in the U.S., which includes B. Braun Interventional Systems, Aesculap® and CAPS®.
Globally, the B. Braun Group of Companies employs more than 58,000 employees in 64 countries. Guided by its Sharing Expertise® philosophy, B. Braun continuously exchanges knowledge with customers, partners and clinicians to address the critical issues of improving care and lowering costs. To learn more about B. Braun Medical, visit www.BBraunUSA.com.